Wire · opportunities
NovaBridge's Visara licenses VIS-102 with $7M payment
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 October 2026 · Fusion42 review
Visara, a subsidiary of NovaBridge Biosciences, has licensed VIS-102 to Wuhan Hiteck Biological Pharma Co. Ltd. for worldwide development and commercialization excluding Greater China, with a $7 million upfront payment and potential $104 million in milestone payments plus royalties. VIS-102 showed promising Phase 1b study results in severe neurotrophic keratitis patients, achieving 50% complete corneal healing at the highest dose after eight weeks.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You can enter the ophthalmology market beyond retinal diseases now that Visara is pushing VIS-102 for corneal healing. Timing your development around upcoming milestones gives you a clear path to partner or licence deals.
◆ Coverage
1 source · 13 Oct 2026
◆ Related on Wire
◆ Topics